Skip to content

Iovance Biotherapeutics

US · IOVA #1864 by market cap Listed 1970
6.90 -0.41 -5.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Founded
2007
CEO
Dr. Frederick G. Vogt, J.D.
Employees
975
Headquarters
San Carlos, California, United States of America
Fiscal year end
12-31
Website
iovance.com

Company profile

Exchange
US
Symbol
IOVA
Market-cap rank
#1864
Listing date
1970-01-01
Market cap
3.19B
Float cap
2.79B
Shares out
462.66M
Float shares
403.97M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:59:47 · For reference only, not investment advice and not tailored to your situation.

Iovance Biotherapeutics discussion 0 comments

Add a comment